Parkinson’s Drug Found Effective Against Brain Metastasis in Breast Cancer
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
- Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- Mn007 Molecules Offer Potential for Combating Streptococcus pyogenes Infection
- Popular Indian Spices Banned in Hong Kong Over Carcinogen Concerns
Parkinson’s Drug Found Effective Against Brain Metastasis in Breast Cancer
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Parkinson’s Drug Found Effective Against Brain Metastasis in Breast Cancer
Researchers have discovered that a discontinued drug originally used to treat Parkinson’s disease symptoms might be effective in treating metastatic breast cancer, particularly the brain metastases it often leads to. This repurposed drug has the potential to become a novel therapy in the fight against cancer.
Breast cancer is a leading cause of brain metastasis, and it is also the most common cause of cancer-related death in women worldwide. Brain metastases in breast cancer are challenging to treat because the body’s protective blood-brain barrier (BBB) typically prevents drugs from penetrating and killing cancer cells.
In a recent study, researchers at Northwestern University Feinberg School of Medicine in the United States have been on the quest for a drug that can penetrate the blood-brain barrier and effectively kill cancer cells. It appears they may have struck gold.
The project’s lead author, Jawad Fares, commented, “The significance of this project lies in its potential to address an urgent clinical challenge: the treatment of brain metastasis, particularly in breast cancer. It offers hope for improving the quality of life and survival outcomes for a significant number of patients with brain metastases, a common and serious complication of cancer. The identification of the novel therapeutic drug metixene and insights into its mechanism add a promising dimension to cancer research and treatment.”
Researchers screened over 320 FDA-approved small-molecule central nervous system inhibitors known to penetrate the BBB. Among the tested drugs, metixene, a discontinued drug previously used to treat Parkinson’s disease symptoms, emerged as the top candidate for killing various subtypes of metastatic breast cancer and brain metastasis cancer cells.
Injecting metixene into mice not only reduced the size of breast cancer tumors but also extended the lifespan of mice with multi-organ metastasis and single or multiple brain metastases.
Researchers observed that metixene induced cancer cells to undergo incomplete autophagy (accumulation of cellular “garbage” that cannot be recycled and reused) by activating the NDRG1 protein, leading to cell death or apoptosis. Knocking out the NDRG1 gene using CRISPR-Cas9 gene editing technology resulted in complete autophagy and the reversal of apoptotic effects.
Fares said, “This research underscores the potential clinical significance of metixene as a treatment drug for metastatic cancers and brain metastatic tumors. Reportedly, this drug has minimal side effects on the human body, making it a strong candidate for clinical translation, which means further research and potential use in clinical trials.”
The study has been published in “The Journal of Clinical Investigation.”
Parkinson’s Drug Found Effective Against Brain Metastasis in Breast Cancer
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
